Skip to main navigationSkip to main content
The University of Southampton
Southampton Health Technology Assessments CentreNews

NICE guidance informed by SHTAC report for treating chronic hepatitis C

Published: 25 May 2018
NICE guidance recommends sofosbuvir–velpatasvir–voxilaprevir as a possible treatment

The National Institute for Health and Care Excellence (NICE) has issued guidance to the national health service (NHS) on the use of the drugs sofosbuvir–velpatasvir–voxilaprevir informed by a report produced by SHTAC.

NICE’s guidance recommends sofosbuvir–velpatasvir–voxilaprevir as a possible treatment for chronic hepatitis C in adults.     

NICE’s guidance is informed by an evidence review group report prepared by SHTAC, which critically appraised the drug company’s submission to NICE’s Single Technology Appraisal process.

For more information about SHTAC’s previous research into hepatitis C please visit our Research page.


We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.